Payment overview · 2025
General Payments
$451.46
20 reported records · 10 companies
Healthcare provider profile · identity verified
Michael Anthony Flores, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DONNA, TX · NPI 1649289497
Verified facts
What the public records show
CMS Open Payments records show Michael Anthony Flores, MD received $451.46 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vraylar by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.65 | 18.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.16 | 15.5% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.17 | 14.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.70 | 12.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.10 | 10.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $42.41 | 9.4% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $31.48 | 7.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.06 | 6.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.87 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.86 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $451.46 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.65 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.16 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $64.17 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.70 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $42.41 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $31.48 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 110 |
| Losartan Potassium | Losartan Potassium | 253 | 84 |
| Omeprazole | Omeprazole | 196 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 76 |
| Metformin Hcl | Metformin Hcl | 186 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 59 |
| Sertraline Hcl | Sertraline Hcl | 169 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 56 |
| Ozempic | Semaglutide | 141 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 48 |
| Trazodone Hcl | Trazodone Hcl | 120 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 36 |
| Lisinopril | Lisinopril | 114 | 42 |
| Gabapentin | Gabapentin | 111 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 41 |
| Alprazolam | Alprazolam | 106 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 36 |
| Januvia | Sitagliptin Phosphate | 97 | 25 |
| Montelukast Sodium | Montelukast Sodium | 97 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 35 |
| Carvedilol | Carvedilol | 89 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 24 |
| Jardiance | Empagliflozin | 81 | 25 |
| Nifedipine Er | Nifedipine | 81 | 36 |
| Donepezil Hcl | Donepezil Hcl | 77 | 29 |
| Furosemide | Furosemide | 76 | 23 |
| Alendronate Sodium | Alendronate Sodium | 67 | 21 |
| Famotidine | Famotidine | 67 | 24 |
| Pregabalin | Pregabalin | 67 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 20 |
| Mounjaro | Tirzepatide | 64 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 28 |
| Azithromycin | Azithromycin | 60 | 50 |
| Myrbetriq | Mirabegron | 58 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 56 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 24 |
| Eliquis | Apixaban | 53 | 12 |
| Aripiprazole | Aripiprazole | 52 | 17 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 16 |
| Memantine Hcl | Memantine Hcl | 49 | 15 |
| Simvastatin | Simvastatin | 49 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 17 |
| Allopurinol | Allopurinol | 48 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 19 |
| Spironolactone | Spironolactone | 47 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Metformin Hcl Er | Metformin Hcl | 43 | 16 |
| Levemir Flexpen | Insulin Detemir | 41 | 12 |
| Mupirocin | Mupirocin | 40 | 28 |
| Dutasteride | Dutasteride | 38 | 11 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | 11 |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 11 |
| Lorazepam | Lorazepam | 33 | 11 |
| Dexamethasone | Dexamethasone | 32 | 28 |
| Prednisone | Prednisone | 32 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Olanzapine | Olanzapine | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | 12 |
| Linzess | Linaclotide | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | 11 |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 14 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Atenolol | Atenolol | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Finasteride | Finasteride | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $451.46 · 20 records | ABBVIE INC. | Azstarys, COBENFY, JARDIANCE, Jornay PM, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error